Your browser doesn't support javascript.
loading
Relationships of circulating CD4+ T cell subsets and cytokines with the risk of relapse in patients with Crohn's disease.
Duclaux-Loras, Rémi; Boschetti, Gilles; Flourie, Bernard; Roblin, Xavier; Leluduec, Jean-Benoit; Paul, Stéphane; Almeras, Thibaut; Ruel, Karine; Buisson, Anthony; Bienvenu, Jacques; Josson, Cendrine; Jasnowski, Renaud; Legastelois, Stéphane; Foussat, Arnaud; Meunier, Camille; Viret, Christophe; Rozieres, Aurore; Faure, Mathias; Kaiserlian, Dominique; Nancey, Stéphane.
Afiliação
  • Duclaux-Loras R; Centre International de Recherche en Infectiologie (CIRI), Univ Lyon, Institut national de la santé et de la recherche médical (Inserm), U1111, Université Claude Bernard Lyon 1, Centre National de Recherche Scientifique (CNRS), UMR5308, Ecole National Supérieur (ENS) de Lyon, Lyon, France.
  • Boschetti G; Department of Gastroenterology, Lyon-Sud Hospital, University Claude Bernard Lyon 1 and Hospices Civils de Lyon, Pierre-Bénite, France.
  • Flourie B; Centre International de Recherche en Infectiologie (CIRI), Univ Lyon, Institut national de la santé et de la recherche médical (Inserm), U1111, Université Claude Bernard Lyon 1, Centre National de Recherche Scientifique (CNRS), UMR5308, Ecole National Supérieur (ENS) de Lyon, Lyon, France.
  • Roblin X; Department of Gastroenterology, Lyon-Sud Hospital, University Claude Bernard Lyon 1 and Hospices Civils de Lyon, Pierre-Bénite, France.
  • Leluduec JB; Centre International de Recherche en Infectiologie (CIRI), Univ Lyon, Institut national de la santé et de la recherche médical (Inserm), U1111, Université Claude Bernard Lyon 1, Centre National de Recherche Scientifique (CNRS), UMR5308, Ecole National Supérieur (ENS) de Lyon, Lyon, France.
  • Paul S; Department of Gastroenterology, Lyon-Sud Hospital, University Claude Bernard Lyon 1 and Hospices Civils de Lyon, Pierre-Bénite, France.
  • Almeras T; Department of Gastroenterology, University Hospital, Saint-Etienne, France.
  • Ruel K; Centre International de Recherche en Infectiologie (CIRI), Univ Lyon, Institut national de la santé et de la recherche médical (Inserm), U1111, Université Claude Bernard Lyon 1, Centre National de Recherche Scientifique (CNRS), UMR5308, Ecole National Supérieur (ENS) de Lyon, Lyon, France.
  • Buisson A; Centre International de Recherche en Infectiologie (CIRI), Univ Lyon, Institut national de la santé et de la recherche médical (Inserm), U1111, Université Claude Bernard Lyon 1, Centre National de Recherche Scientifique (CNRS), UMR5308, Ecole National Supérieur (ENS) de Lyon, Lyon, France.
  • Bienvenu J; Laboratory of Immunology and Immunomonitoring, University Hospital, Université de Lyon, Saint-, Etienne, France.
  • Josson C; Centre International de Recherche en Infectiologie (CIRI), Univ Lyon, Institut national de la santé et de la recherche médical (Inserm), U1111, Université Claude Bernard Lyon 1, Centre National de Recherche Scientifique (CNRS), UMR5308, Ecole National Supérieur (ENS) de Lyon, Lyon, France.
  • Jasnowski R; Centre International de Recherche en Infectiologie (CIRI), Univ Lyon, Institut national de la santé et de la recherche médical (Inserm), U1111, Université Claude Bernard Lyon 1, Centre National de Recherche Scientifique (CNRS), UMR5308, Ecole National Supérieur (ENS) de Lyon, Lyon, France.
  • Legastelois S; Department of Gastroenterology, University Hospital, Clermont-Ferrand, France.
  • Foussat A; Laboratory of Immunology, Hospices Civils de Lyon, Hopital Lyon-Sud, Pierre-Bénite, France.
  • Meunier C; Advanced Bioscience Laboratories (ABL), Lyon, France.
  • Viret C; Advanced Bioscience Laboratories (ABL), Lyon, France.
  • Rozieres A; Indicia, Lyon, France.
  • Faure M; TxCell, Sophia-Antipolis, France.
  • Kaiserlian D; Centre International de Recherche en Infectiologie (CIRI), Univ Lyon, Institut national de la santé et de la recherche médical (Inserm), U1111, Université Claude Bernard Lyon 1, Centre National de Recherche Scientifique (CNRS), UMR5308, Ecole National Supérieur (ENS) de Lyon, Lyon, France.
  • Nancey S; Department of Gastroenterology, Lyon-Sud Hospital, University Claude Bernard Lyon 1 and Hospices Civils de Lyon, Pierre-Bénite, France.
Front Immunol ; 13: 864353, 2022.
Article em En | MEDLINE | ID: mdl-36405740
ABSTRACT
Background and

aims:

We aimed to analyze circulating CD4+ T cell subsets and cytokines during the course of Crohn's disease (CD). Methods and

results:

CD4+ T cell subsets, ultrasensitive C-reactive protein (usCRP), and various serum cytokines (IL-6, IL-8, IL-10, IL-13, IL-17A, IL-23, TNFα, IFNγ, and TGFß) were prospectively monitored every 3 months for 1 year, using multicolor flow cytometry and an ultrasensitive Erenna method in CD patients in remission at inclusion. Relapse occurred in 35 out of the 113 consecutive patients (31%). For patients in remission within 4 months prior to relapse and at the time of relapse, there was no significant difference in Th1, Th17, Treg, and double-positive CD4+ T cell subsets co-expressing either IFNγ and FOXP3, IL-17A and FOXP3, or IFNγ and IL-17A. On the contrary, in patients who remained in remission, the mean frequency and number of double-positive IL-17A+FOXP3+ CD4+ T cells and the level of usCRP were significantly higher (p ≤ 0.01) 1 to 4 months prior to relapse. At the time of relapse, only the IL-6 and usCRP levels were significantly higher (p ≤ 0.001) compared with those patients in remission. On multivariate analysis, a high number of double-positive IL-17A+FOXP3+ CD4+ T cells (≥1.4 cells/mm3) and elevated serum usCRP (≥3.44 mg/L) were two independent factors associated with risk of relapse.

Conclusions:

Detection of circulating double-positive FOXP3+IL-17A+ CD4+ T cell subsets supports that T cell plasticity may reflect the inflammatory context of Crohn's disease. Whether this subset contributes to the pathogenesis of CD relapse needs further studies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Doença de Crohn / Interleucina-17 Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Doença de Crohn / Interleucina-17 Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França